Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
The COVID-19 pandemic has had widespread effects across the globe, and its causative agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end this pandemic. Single and combination therapies with monoclonal antibodies have received emergency use authorization, and more treatments are under development. Furthermore, multiple vaccine constructs have shown promise, including two […]
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 Read More »